戻る Agenda
FDA Collaborations Broaden the Reach of Health Care Messages to Effectively Communicate with the Public
Session Chair(s)
Anna Fine, PHARMD, MS
Interim Director for ClinicalTrials.gov
National Institutes of Health (NIH), United States
This session will provide an understanding of FDA's innovative collaborative programs to extend the reach of communication from the agency to inform and educate the public about potential risks associated with use of regulated products.
Learning Objective : Describe innovative collaboration models with FDA for communicating safety information; Identify variety of programs as a result of the collaboration models; Recognize the FDA regulatory framework for collaborations and identify opportunity for future collaborations with FDA.
Speaker(s)
A New Vision: Leveraged Opportunities to Improve Public Health
Michael Duenas
American Optometric Association, United States
Chief Public Health Officer
Innovation in Collaboration: Lessons from Public-Private Partnerships
Amy Nadel
Medscape, United States
Executive Director, Professional Relationships